Your browser doesn't support javascript.
loading
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute, Ruth M; Pawlyn, Charlotte; Cairns, David A; Davies, Faith E; Menzies, Tom; Rawstron, Andy; Jones, John R; Hockaday, Anna; Henderson, Rowena; Cook, Gordon; Drayson, Mark T; Jenner, Matthew W; Kaiser, Martin F; Gregory, Walter M; Morgan, Gareth J; Jackson, Graham H; Owen, Roger G.
Afiliación
  • de Tute RM; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
  • Pawlyn C; The Institute of Cancer Research, London, United Kingdom.
  • Cairns DA; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Davies FE; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Menzies T; Perlmutter Cancer Center, NYU Langone Health, New York, NY.
  • Rawstron A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Jones JR; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
  • Hockaday A; Eastbourne District General Hospital, Eastbourne, United Kingdom.
  • Henderson R; Brighton and Sussex Medical School, University of Sussex, Sussex, United Kingdom.
  • Cook G; Kings College Hospital, NHS Foundation Trust, London, United Kingdom.
  • Drayson MT; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Jenner MW; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Kaiser MF; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Gregory WM; Kings College Hospital, NHS Foundation Trust, London, United Kingdom.
  • Morgan GJ; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.
  • Jackson GH; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Owen RG; The Institute of Cancer Research, London, United Kingdom.
J Clin Oncol ; 40(25): 2889-2900, 2022 09 01.
Article en En | MEDLINE | ID: mdl-35377708
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Mieloma Múltiple Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Oncol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Mieloma Múltiple Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Oncol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido